Mass Spectrometry as Alternative Method to Identify and Monitor Non-Secretory Progressive Disease in Patients with Multiple Myeloma.
Cristina AgullóNoemí PuigTeresa ContrerasSergio CastroBorja PuertasVerónica González De La CalleBeatriz Rey BúaMaria-Victoria Mateos-MantecaPublished in: Biomedicines (2024)
The higher sensitivity of the mass spectrometry methods to detect the MP in patients with myeloma and other monoclonal gammopathies translates into better identification of the disease progression, permits the inclusion of more patients in clinical trials and facilitates treatment monitoring.
Keyphrases
- mass spectrometry
- multiple myeloma
- clinical trial
- newly diagnosed
- liquid chromatography
- end stage renal disease
- ejection fraction
- multiple sclerosis
- chronic kidney disease
- high resolution
- capillary electrophoresis
- gas chromatography
- prognostic factors
- high performance liquid chromatography
- randomized controlled trial
- patient reported outcomes
- study protocol
- tandem mass spectrometry
- smoking cessation
- open label
- simultaneous determination